UK pharmaceutical to spin off brands such as Sensodyne, Voltaren and Panadol into Haleon in largest listing since 2011
Investors in the British pharmaceuticals giant GSK have voted to approve a demerger of its consumer brands into a new company, Haleon, firing the starting gun on the largest London stock market listing in a decade.
Shares in Haleon are scheduled to start trading on Monday 18 July, after investors in GSK – previously GlaxoSmithKline – voted to approve the demerger. The FTSE 100 company won 99.8% of the votes cast at a general meeting on Wednesday at a hotel by London’s Heathrow airport.